Dimethylglycine deficiency and the development of diabetes

Diabetes

Volumn 64, Issue 8, 2015, Pages 3010-3016

  Magnusson, Martin ^a,b   Wang, Thomas J ^c   Clish, Clary ^d   Engström, Gunnar ^b   Nilsson, Peter ^a,b   Gerszten, Robert E ^d,e   Melander, Olle ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLGLYCINE; GLUCOSE; GLYCINE; HEMOGLOBIN A1C; INSULIN; DIMETHYLGLYCINE DEHYDROGENASE; SARCOSINE;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIMETHYLGLYCINE DEFICIENCY; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; PRIORITY JOURNAL; AGED; ALLELE; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; GENOTYPE; METABOLOME; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; ALLELES; DIABETES MELLITUS, TYPE 2; DIMETHYLGLYCINE DEHYDROGENASE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLOME; MIDDLE AGED; SARCOSINE;

EID: 84943184774     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1863     Document Type: Article

References (35)

1. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
2. Newsholme P, Bender K, Kiely A, Brennan L. Amino acid metabolism, insulin secretion and diabetes. Biochem Soc Trans 2007;35:1180-1186
3. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
4. Wang TJ, Ngo D, Psychogios N, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest 2013;123:4309-4317
5. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639-648
6. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012;8:615
7. Michaliszyn SF, Sjaarda LA, Mihalik SJ, et al. Metabolomic profiling of amino acids and b-cell function relative to insulin sensitivity in youth. J Clin Endocrinol Metab 2012;97:E2119-E2124
8. Xie W, Wood AR, Lyssenko V, et al.; MAGIC Investigators; DIAGRAM Consortium; GENESIS Consortium; RISC Consortium. Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes. Diabetes 2013;62:2141-2150
9. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-580
10. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122
11. Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099
12. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 2008;138:914-920
13. Rhee EP, Ho JE, Chen MH, et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab 2013;18:130-143
14. Illig T, Gieger C, Zhai G, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010;42:137-141
15. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222-2231
16. Magnusson M, Lewis GD, Ericson U, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J 2013;34:1982-1989
17. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187
18. Berglund G, Elmstähl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993;233:45-51
19. Manjer J, Carlsson S, Elmstähl S, et al. The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001;10:489-499
20. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 2005;179:325-331
21. Berglund G, Nilsson P, Eriksson KF, et al. Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med 2000;247:19-29
22. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63
23. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-2108
24. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjörnsdottir S; Swedish National Diabetes Register. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 2008;31:2038-2043
25. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 2001;17:983-989
26. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450
27. Centre for Epidemiology, National Board of Health and Welfare. A Finger on the Pulse: Monitoring Public Health and Social Conditions in Sweden 1992-2002. Stockholm, National Board of Health and Welfare, 2003
28. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735
29. Enhörning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 2013;37:598-603
30. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-2232
31. Binzak BA, Wevers RA, Moolenaar SH, et al. Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. Am J Hum Genet 2001;68:839-847
32. Moolenaar SH, Poggi-Bach J, Engelke UF, et al. Defect in dimethylglycine dehydrogenase, a new inborn error of metabolism: NMR spectroscopy study. Clin Chem 1999;45:459-464
33. Ho JE, Larson MG, Vasan RS, et al. Metabolite profiles during oral glucose challenge. Diabetes 2013;62:2689-2698
34. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. Am J Physiol Endocrinol Metab 2007;292:E1157-E1165
35. Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids 2013;45:463-477